Randox Wins NI Hospital Trusts Business
News Dec 09, 2013
The contract will see the County Antrim firm supply quality control products to all ten hospitals within the NI Trusts. The new business is worth potentially £1.2m over the life of the contract.
The deal means that routine patient blood tests carried out in any NHS hospital or clinic in Northern Ireland will be quality assured by Randox products developed and manufactured in Crumlin.
A high percentage of medical appointments in Northern Ireland result in patient blood samples being taken before being tested in laboratories. Diagnosis of an illness or medical condition, and the subsequent treatment prescribed, will be given by a doctor based on the results of these blood tests.
Robust Quality Control is the bedrock of patient blood testing as it helps laboratories ensure accuracy in their testing procedures. If errors occur during testing this can result in misdiagnosis and delayed treatment, which can ultimately be life threatening for the patient.
Randox is one of the largest manufacturers of laboratory quality control products in the world. The products, all manufactured in Country Antrim, are widely considered to be the most accurate quality controls available globally. As part of the deal Randox has developed a range of customised quality controls specifically to match the clinical requirements of the NI Hospital Trusts.
Health Minister Edwin Poots, who visited Randox today as part of the announcement, said,
“Northern Ireland’s biotechnology sector is world-class and a growing contributor to the local economy. I am delighted that patients in Northern Ireland will now benefit from quality assured diagnostic products developed and manufactured in Crumlin.
“Today's announcement is a further example of the positive mutual benefits to health and the economy that can result from partnership working between Government and the Pharmaceutical and Biotechnology Industry. I am keen to continue this work to ensure that we can continue to grow our pharmaceutical and biotechnology capacity in Northern Ireland.”
Steven Jordan Global Manager, Randox Quality Control lauded the positive contribution the company is making in improving the health of Northern Ireland’s population and, ultimately, saving lives.
“Randox’s reputation as a leader in diagnostics is recognised across the world. We are a ground-breaking biotechnology company, committed to revolutionising healthcare and diagnostics at a global level. We are delighted that the people of Northern Ireland will now be able to benefit from this level of global expertise, ensuring more accurate and reliable diagnosis, and improving the health outlook for all.”
Penn Medicine Biochemist Receives Major Award for Research on Epigenetic Protein Modifications via Mass SpecNews
Benjamin A.Garcia, PhD, an expert in quantitative proteomics and Presidential Professor of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, has been awarded the Biemann Medal by the American Society for Mass Spectrometry (ASMS). The early-career award recognizes significant achievement in basic or applied mass spectrometry.
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Automated Robotic Device Enables Faster Blood TestingNews
Rutgers researchers have created an automated blood drawing and testing device that provides rapid results, potentially improving the workflow in hospitals and other health-related institutions to allow health care practitioners to spend more time treating patients.READ MORE